NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Ex Vivo Evaluation of Immunity Activation Face to S. Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients

NCT03643328

CompletedNA

Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Conditions: Staphylococcus Aureus

Interventions: blood samples, nasal swabs

Countries: France

S. aureus is a leading cause of severe infections notably in haemodialysis patients. These patients have a high risk of S. aureus nasal carriage, with a rate of persistent carriage near 30%. These carriers are particularly at risk of S. aureus infections as we previously shown. High risk of S. aureus infections such as bacteremia occurred notably in patients with dialysis catheters. Decolonization of carriers may prevent such infections however this approach has limits. Development of an effective S. aureus vaccine is crucial. To date, past vaccines tested (phase III) failed to achieve their end points. Target of only one or few antigens, absence of cellular response induction and possibly no impact on carriage are probably the reasons of the failures.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Patient starting haemodialysis for chronic hemodialysis.
* Patient starting haemodialysis on catheter
* Patient who signed the informed consent form

Exclusion Criteria:

* Pregnant woman
* Patient who starts Haemodialysis for over 3 months
* Patient with anemia (hemoglobin \<7 g / dL)

Locations (1)

Saint-Etienne, France